Pharma noshes at the biotech buffet

If 2007 was the year pharma woke up to biotech, then 2008 will be time for brunch. Drug makers will continue to serve themselves from the biologics buffet, whether by gobbling up entire companies or by snacking on a bit of this candidate and a bit of that one through licensing deals. Plus, back in the R&D kitchen, Big Pharma is working on its own biotech recipes, though none of them are likely to be ready for sampling yet.

There's one potential wrinkle in the tablecloth, though: Reportedly, "momentum is building" for a new FDA pathway for generic biologic drugs (biosimilars). In June, a Senate committee approved legislation that would open that door; now, the House is preparing to consider a similar bill. And biosimilars already are taking hold in Europe. Last week, regulators approved a copycat form of Epogen, the blockbuster anemia drug made by biotech big wheel Amgen.

- here's more about Pharma's anemia-centric love for biotech
- see this article on biosimilar legislation in the U.S.

Suggested Articles

Pfizer has scored FDA approval for its Humira biosimilar, but it can't launch the product for several years under a patent settlement.

The 3-2 vote on the deal was split along the party lines, spelling trouble for future biopharma M&A deals should Democrats move into the White House.

Recipharm has been building its capabilities in sterile injectable and inhalation drugs. Now it is buying a CDMO that manufactures devices for both.